Metropolitan Life Insurance Co. NY raised its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 5.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,473 shares of the biopharmaceutical company’s stock after buying an additional 1,299 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Ultragenyx Pharmaceutical were worth $1,794,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in the company. Fortaleza Asset Management Inc. increased its position in shares of Ultragenyx Pharmaceutical by 148.5% in the first quarter. Fortaleza Asset Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 980 shares during the last quarter. Pacer Advisors Inc. increased its position in shares of Ultragenyx Pharmaceutical by 22.6% in the first quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 560 shares during the last quarter. Strs Ohio increased its position in shares of Ultragenyx Pharmaceutical by 10.7% in the first quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 300 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Ultragenyx Pharmaceutical by 3.7% in the first quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 115 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV purchased a new position in shares of Ultragenyx Pharmaceutical during the first quarter valued at approximately $237,000. Hedge funds and other institutional investors own 95.25% of the company’s stock.
Ultragenyx Pharmaceutical Inc. (RARE) opened at 70.99 on Friday. The firm’s 50-day moving average is $62.37 and its 200-day moving average is $67.89. The stock’s market capitalization is $3.00 billion. Ultragenyx Pharmaceutical Inc. has a 12 month low of $51.67 and a 12 month high of $91.35.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.71) by $0.08. During the same period last year, the company earned ($1.35) EPS. On average, equities analysts expect that Ultragenyx Pharmaceutical Inc. will post ($7.04) earnings per share for the current fiscal year.
RARE has been the topic of several analyst reports. Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday. Canaccord Genuity reaffirmed a “buy” rating and issued a $100.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Thursday, March 23rd. SunTrust Banks, Inc. lifted their target price on shares of Ultragenyx Pharmaceutical from $100.00 to $105.00 and gave the stock a “buy” rating in a research note on Wednesday, April 19th. Robert W. Baird reaffirmed an “outperform” rating and issued a $90.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, April 19th. Finally, Jefferies Group LLC downgraded shares of Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating and decreased their target price for the stock from $109.00 to $66.00 in a research note on Thursday, April 6th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $85.71.
In other news, VP Theodore Alan Huizenga sold 480 shares of the company’s stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $57.46, for a total transaction of $27,580.80. Following the completion of the transaction, the vice president now directly owns 9,366 shares of the company’s stock, valued at approximately $538,170.36. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 9.20% of the company’s stock.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE).
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
